Resistance-Proof Therapeutics

Next-generation precision medicines

Learn more



 

Autonomous Therapeutics

is pioneering new classes of nucleic acids that are target-activated and variant-agnostic from influenza to colon cancer.

 

Press & Media

Featured
Autonomous Therapeutics and Mink Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
Autonomous Therapeutics and Mink Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
Read more →
Autonomous CEO, Dr. Ariel Weinberger, serves on keynote panel at World Vaccine & Immunotherapy Congress
Autonomous CEO, Dr. Ariel Weinberger, serves on keynote panel at World Vaccine & Immunotherapy Congress
Read more →
Autonomous CEO, Dr. Ariel Weinberger, gives plenary presentation at NIH Synthetic Biology Consortium Meeting
Autonomous CEO, Dr. Ariel Weinberger, gives plenary presentation at NIH Synthetic Biology Consortium Meeting
Read more →
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
Read more →
Keynote Panel @ RNA Leaders USA Congress
Keynote Panel @ RNA Leaders USA Congress
Read more →
Op-Ed in BioCentury: The urgent need for variant-proof therapeutics
Op-Ed in BioCentury: The urgent need for variant-proof therapeutics

Warp speed isn’t fast enough: the need for variant-proof therapeutics

Broad-spectrum vaccines and therapies are needed to get ahead of the next pandemic, and stay ahead of viral variants

Read more →
See more
 
 

Contact

Autonomous Therapeutics, Inc.
1530 East Jefferson Street
Rockville, MD 20852 

 

info@autonomous.bio